Clinical Trials Logo

Benign Prostatic Hypertrophy clinical trials

View clinical trials related to Benign Prostatic Hypertrophy.

Filter by:

NCT ID: NCT05768776 Not yet recruiting - Clinical trials for Benign Prostatic Hypertrophy

Outpatient Holmium LASER Enucleation of the Prostate: Benefit of MOSES(TM) 2.0 Technology

MOSES
Start date: April 2023
Phase:
Study type: Observational

The aim of this study is to compare the success rate of outpatient surgery after holmium LASER enucleation of the prostate (HoLEP) for the treatment of BPH with and without the use of the MOSES 2.0 effect.

NCT ID: NCT05308017 Completed - Clinical trials for Benign Prostatic Hypertrophy

Wolf 24 F vs. Storz 28 F Laser Sheath Size for HoLEP

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to compare two different types of scopes that can be used for HoLEP. HoLEP is performed through the urethra using a Laser scope to remove obstructing prostate tissue. Laser scopes come in different sizes (diameters).

NCT ID: NCT05082142 Completed - Urologic Diseases Clinical Trials

Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)

Start date: September 17, 2021
Phase: Phase 4
Study type: Interventional

This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP). The investigators attempt to perform HoLEP as a same-day discharge (SDD) procedure, but at Northwestern Memorial, the SDD rate is currently approximately 60%. The limiting factor in SDD is hematuria. Tranexamic acid (TXA) is a clot promoting drug that is commonly used by orthopedic, cardiac and obstetric surgeons to prevent bleeding. The primary outcome will be to assess if there is a difference in SDD rates in those who receive TXA vs. those who do not. Secondary outcomes will assess bleeding complications (defined as unplanned ED visit/clinic visit/procedure/admission related to bleeding, clot retention, clot evacuation, need for perioperative transfusion) between participants who receive TXA vs. those do not. The study will also assess differences in perioperative complications associated with TXA including but not limited to: deep venous thrombosis, pulmonary embolism, cerebrovascular events, between the groups. The study will also assess for the duration of postoperative hematuria between groups as well as differences in operative times between the groups. The investigators anticipate that there may be up to a 25% increase in SDD rates in those who receive TXA vs. those who do not.

NCT ID: NCT04781049 Completed - Clinical trials for Benign Prostatic Hyperplasia

Transperineal Laser Ablation vs Transurethral Resection for Benign Prostatic Obstruction: A Randomized Clinical Trial

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The primary objective of the study is to compare Trans-Perineal Laser Ablation of Prostate versus Trans-Urethral Resection of Prostate in the immediate impact on post-operative pain; in terms of relief in benign prostatic obstruction and preservation of the ejaculatory function in the short term (at 1, 3 and 6 months). The secondary objective of the study is the evaluation of the long-term deobstructive effectiveness (12 months).

NCT ID: NCT04398420 Terminated - Clinical trials for Benign Prostatic Hypertrophy

Transurethral Vapor Enucleation Resection of the Prostate (TVERP), Bipolar TURis and HoLEP

Start date: August 27, 2020
Phase: N/A
Study type: Interventional

To verify the safety and efficacy of the use of the plasma vaporisation button in Transurethral Vapor Enucleation and Resection of the prostate (TVERP) for treatment of Benign prostatic hypertrophy (BPH) patients with prostate ˃30 and ≤80 ml compare to TURis or HoLEP surgery methods.

NCT ID: NCT03630926 Active, not recruiting - Prostate Cancer Clinical Trials

Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.

VPAC
Start date: October 16, 2018
Phase:
Study type: Observational

This is a double-blind, study to evaluate the performance of NV-VPAC1 PCa Urine Diagnostic Test in three distinct populations being treated at the Intermountain Urology Clinic. The first population (positive control) is comprised of men with biopsy-confirmed PCa who are scheduled for prostatectomy. The second population (negative control) is comprised of men with benign prostatic hypertrophy (BPH) who are scheduled for transurethral resection of the prostate (TURP). The third population (negative control) is comprised of men or women with bladder/kidney stones who are scheduled for a cystoscopy.

NCT ID: NCT03423979 Active, not recruiting - Clinical trials for Benign Prostatic Hyperplasia

Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter

EVEREST-I
Start date: December 19, 2017
Phase: Phase 2
Study type: Interventional

A prospective, non-randomized study. The subjects will be enrolled and treated with the Optilume BPH Prostatic DCB Dilation Catheter System at up to 8 clinical sites. The post-treatment follow-up visit can be up to 5 years. The objective of the study is to evaluate the safety and efficacy of the Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter System in the treatment of BPH.

NCT ID: NCT02676544 Terminated - Clinical trials for Lower Urinary Tract Symptoms

Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)

Start date: December 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective, open label single center feasibility study to demonstrate basic safety and effectiveness of prostate artery embolization for the treatment of symptomatic benign prostatic Hyperplasia (BPH) in a small series of patients with large (≥90 grams) glands.

NCT ID: NCT02533687 Suspended - Clinical trials for Benign Prostatic Hypertrophy

Comparison of Different Energy Sources During TUR-P

Start date: July 2020
Phase: N/A
Study type: Interventional

With this study, it is aimed to compare the operative results and complication rates in transurethral resection of the prostate (TUR-P) performed by resectoscopes with two different bipolar and a monopolar energy sources.

NCT ID: NCT02509975 Completed - Clinical trials for Benign Prostatic Hyperplasia

Safety and Efficacy of OCL 503 in Prostate Artery Embolization

Start date: September 2015
Phase: N/A
Study type: Interventional

This is a prospective, pilot, open-label, uncontrolled, non-randomized safety and effectiveness study of OCL 503 in men with BPH.